International Journal of Medical Informatics, Journal Year: 2024, Volume and Issue: 191, P. 105581 - 105581
Published: July 30, 2024
Language: Английский
Kidney International, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
0
Kidney Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 101013 - 101013
Published: April 1, 2025
Language: Английский
Citations
0
Frontiers in Medicine, Journal Year: 2021, Volume and Issue: 7
Published: Jan. 21, 2021
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding DKD pathophysiology. The complement system is a central part innate immunity, but its dysregulated activation detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests DKD. With existent drugs clinical success treating other diseases, inhibition has emerged as potential novel therapy to halt the progression This article will review DKD, system's role non-diabetic disease, benefits targeting therapies especially for patients.
Language: Английский
Citations
24
Diagnostics, Journal Year: 2022, Volume and Issue: 12(5), P. 1205 - 1205
Published: May 11, 2022
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. Along with the increasing prevalence diabetes, DKD expected to affect higher number patients. Despite major progress in therapy and diabetes mellitus (DM), classic clinical diagnostic tools remain insufficient, delaying proper diagnosis therapeutic interventions. We put forward thesis that there need for novel markers will be early, specific, non-invasively obtained. The ongoing investigations uncover new molecules may potentially become DKD—among those are: soluble α-Klotho proteases (ADAM10, ADAM17, cathepsin, dipeptidyl peptidase 4, caspase, thrombin, circulating microRNAs). This review summarizes current state-of-the-art selection potential markers, based on up-to-date literature.
Language: Английский
Citations
18
Diabetes Metabolic Syndrome and Obesity, Journal Year: 2022, Volume and Issue: Volume 15, P. 1845 - 1864
Published: June 1, 2022
Dipeptidyl-peptidase-4 (DPP-4) is an enzyme having various properties and physiological roles in lipid accumulation, resistance to anticancer agents, immune stimulation. DPP-4 includes membrane-bound peptidases a kind of that cleaves alanine or proline-containing peptides such as incretins, chemokines, appetite-suppressing hormones (neuropeptide) at their N-terminal dipeptides. plays role the final breakdown produced by other endo exo-peptidases from nutritious proteins absorption these tissues. activity has different modes action on glucose metabolism, hunger regulation, gastrointestinal motility, system function, inflammation, pain regulation. According literature survey, levels increase individuals with liver conditions, up-regulation hepatic expression likely be cause intolerance insulin resistance. This review majorly focuses cleavage incretins its resulting conditions like level elevation due some conditions. Thus, we have discussed effects diseases hepatitis C, non-alcoholic fatty liver, regeneration stem cell, hepatocellular carcinoma, impact elevated association treatment drug choices. In addition, effect inhibitors obesity negative aspects are also brief.
Language: Английский
Citations
18
Nephrology Dialysis Transplantation, Journal Year: 2022, Volume and Issue: 38(3), P. 630 - 643
Published: April 7, 2022
Abstract Background Chronic kidney disease (CKD), a serious complication of type 2 diabetes (T2D) increases the comorbid risk cardiovascular (CVD) and end-stage (ESKD). Treatment guidelines recommend renin–angiotensin blockade antihyperglycemic treatment with metformin sodium-glucose cotransporter inhibitors (SGLT2is) as first-line treatment. We evaluated initiation discontinuation overall in subgroups T2D patients incident CKD (incident cohort) rates clinical economic outcomes any (prevalent cohort). Methods In this retrospective study administrative claims USA between 1 January 2007 31 March 2019, we proportion concomitant, newly initiated discontinued use antihypertensive [angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blockers (ARBs), steroidal mineralocorticoid antagonists (sMRAs)] antidiabetic [SGLT2is, dipeptidyl peptidase-4 (DPP4is), glucagon-like peptide-1 agonists (GLP-1 RAs), insulin sulfonylureas] medications, per 1000 person-years mean total healthcare costs. Results identified 63 127 326 763 prevalent cohorts, respectively. Low high were observed 17.8% 56.0% for ACEi/ARBs, 1.3% 66.0% sMRAs, 2.5% 65.0% SGLT2is, 3.7% 66.8% DPP4is, 2.31% 69.0% GLP-1 RAs, 4% 75.7% 5.5% 56.9% sulfonylureas. Similar results seen by subgroups. Rates ranged from 35.07 all-cause mortality to 104.19 ESKD, hospitalization ranging 36.61 hospitalizations 283.14 hospitalizations. Among comorbidities, higher found. Conclusion Our highlight unmet needs T2D, particularly multimorbid CVD, high-risk (low estimated glomerular filtration rate or urinary albumin:creatinine ratio) rapidly progressing CKD. recommended treatments suggest that adherence halting progression is suboptimal. These may benefit further options improve morbidity reduce burden.
Language: Английский
Citations
16
Fundamental and Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 38(6), P. 1059 - 1068
Published: June 24, 2024
Abstract Background Monotherapy to treat obesity‐associated liver insult is limited. Objectives In diet‐induced obese mice showing metabolic dysfunction‐associated steatotic disease (MASLD), we aimed compare the combinations of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase‐4 (DPP4i, linagliptin, L), and glucagon‐like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D). Methods Male 3‐month‐old C57BL/6J were fed for 12 weeks in a control (C, n = 10) or high‐fat (HF, 30) diet. Then, followed three additional weeks: C, HF, HF E + L, D ( 10/group). Results versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), resistance (+68%). Compared group, L lower (−60%), (−61%), (−46%), TAG (−58%), (−71%), (−62%), (−82%). The principal component analysis (PCA) placed group on opposite sides, while was between D. Conclusion PCA separated groups considering metabolism‐related genes (glucose lipid), mitochondrial biogenesis, steatosis. two pharmacological beneficial effects treating obesity MASLD. However, combination SGLT2i GLP1RA more potent MASLD than DPP4i and, therefore, should be recommended combination.
Language: Английский
Citations
3
Clinical Science, Journal Year: 2024, Volume and Issue: 138(16), P. 991 - 1007
Published: Aug. 1, 2024
Abstract Cellular senescence represents a condition of irreversible cell cycle arrest, characterized by heightened senescence-associated beta-galactosidase (SA-β-Gal) activity, secretory phenotype (SASP), and activation the DNA damage response (DDR). Diabetic kidney disease (DKD) is significant contributor to end-stage renal (ESRD) globally, with ongoing unmet needs in terms current treatments. The role pathogenesis DKD has attracted substantial attention evidence premature this condition. process cellular appears be associated mitochondrial redox pathways, autophagy, endoplasmic reticulum (ER) stress. Increasing accumulation senescent cells diabetic not only leads an impaired capacity for repair injury, but also secretion pro-inflammatory profibrotic cytokines growth factors causing inflammation fibrosis. Current treatments diabetes exhibit varying degrees renoprotection, potentially via mitigation kidney. Targeting clearance through pharmaceutical interventions could emerge as promising strategy preventing treating DKD. In paper, we review understanding summarize possible therapeutic relevant field.
Language: Английский
Citations
3
Clinical Kidney Journal, Journal Year: 2023, Volume and Issue: 16(6), P. 1005 - 1013
Published: Jan. 27, 2023
Ex vivo confocal microscopy is a real-time technique that provides high-resolution images of fresh, non-fixed tissues, with an optical resolution comparable to conventional pathology. The objective this study was investigate the feasibility using ex in fusion mode (FuCM) and haematoxylin eosin (H&E)-like digital staining results for analysis basic patterns lesion nephropathology.Forty-eight renal samples were scanned fourth-generation device. Samples subjected imaging then processed pathology techniques. Concordance between techniques evaluated by means percentage agreement κ index.Agreement H&E-like strong (κ = 0.88) evaluation acute tubular damage substantial 0.79) interstitial fibrosis, inflammation, arterial arteriolar lesions. also allows rapid identification extracapillary proliferation 0.88), necrosis segmental sclerosis .88) glomerular compartment, but reported here are limited because small number cases these findings.FuCM proved be as effective evaluating presence fibrosis changes, fresh tissue. ease acquisition suggests FuCM may useful kidney biopsies restructure clinical workflow histopathology.
Language: Английский
Citations
7
European Journal of Clinical Investigation, Journal Year: 2023, Volume and Issue: 53(8)
Published: April 1, 2023
There is a lack of consensus on prescribing alternatives to initial metformin therapy and intensification for type 2 diabetes mellitus (T2DM) management. This review aimed identify/quantify factors associated with specific antidiabetic drug classes T2DM.Five databases (Medline/PubMed, Embase, Scopus, Web Science) were searched using the synonyms each concept (patients T2DM, drugs influencing prescribing) in both free text Medical Subject Heading (MeSH) forms. Quantitative observational studies evaluating metformin, sulfonylurea, thiazolidinedione, Dipeptidyl-peptidase 4 inhibitors (DPP4-I), sodium glucose transporter (SGLT2-I), Glucagon-Like peptide receptor agonist (GLP1-RA) insulin outpatient settings published from January 2009 2021 included. Quality assessment was performed Newcastle-Ottawa scale. The validation done 20% identified studies. pooled estimate measured three-level random-effect meta-analysis model based odds ratio [95% confidence interval]. Age, sex, body mass index (BMI), glycaemic control (HbA1c) kidney-related problems quantified.Of 2331 studies, 40 met selection criteria. Of which, 36 31 included sex age, respectively, while 20 examined baseline BMI, HbA1c problems. majority (77.5%, 31/40) rated as good despite that overall heterogeneity studied factor more than 75%, it mostly related within-study variance. Older age significantly higher sulfonylurea prescription (1.51 [1.29-1.76]), yet lower (0.70 [0.60-0.82]), SGLT2-I (0.57 [0.42-0.79]) GLP1-RA (0.52 [0.40-0.69]); BMI showed opposite significant results (sulfonylurea: 0.76 [0.62-0.93], metformin: 1.22 [1.08-1.37], SGLT2-I: 1.88 [1.33-2.68], GLP1-RA: 2.35 [1.54-3.59]). Both having (0.74 [0.57-0.97], 0.39 [0.25-0.61]), but prescriptions (2.41 [1.87-3.10], 1.52 [1.10-2.10]). Also, DPP4-I patients (1.37 [1.06-1.79]) among (0.82 [0.68-0.99]). Sex thiazolidinedione (F:M; 1.38 [1.19-1.60] 0.91 [0.84-0.98]).Several potential determinants prescribing. magnitude significance differed by class. Patient's had most association choice four out seven followed which an impact three drugs, whereas least decision only.
Language: Английский
Citations
7